2025 · Enclomiphene
Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
Hohl A, et al. · Arch Endocrinol Metab, 2025
Link to study: Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
Pooling the randomized trials, clomiphene/enclomiphene raised total testosterone by about 274 ng/dL versus placebo and increased LH, with no significant testosterone difference versus testosterone gel, supporting SERMs as an alternative to gel.
Conventional / MD reading
- The strongest synthesis to date: across trials, SERMs raised total testosterone ~274 ng/dL vs placebo with higher LH, a reasonable oral alternative to gel in secondary hypogonadism.
- Still notes short follow-up and heterogeneous trials; long-term outcomes remain thin.
Functional & integrative reading
- Reads the LH rise as the mechanism worth wanting: the body makes its own testosterone rather than receiving it.
- Treats the alternative-to-gel framing as the headline, especially where fertility matters.
Point of divergence: Does a robust short-term testosterone rise justify routine use, or does the thin long-term record still argue for caution?
2024 · Enclomiphene
Enclomiphene versus clomiphene citrate for hypogonadism: testosterone, estradiol and side effects
Saffati G, et al. (Baylor) · Transl Androl Urol, 2024
Link to study: Enclomiphene versus clomiphene citrate for hypogonadism: testosterone, estradiol and side effects
A retrospective comparison: enclomiphene raised testosterone at least as well as clomiphene (median +166 ng/dL) with a smaller estradiol rise and markedly fewer side effects (odds ratio 0.18).
Conventional / MD reading
- Enclomiphene matched or beat clomiphene on testosterone (median +166 ng/dL) with less estradiol rise and far fewer adverse events (OR 0.18).
- Retrospective and modest in size; supports preference for the purified isomer but is not a randomized comparison.
Functional & integrative reading
- Explains the tolerability gap mechanistically: clomiphene carries an estrogenic isomer (zuclomiphene) that enclomiphene leaves out.
- Reinforces choosing the cleaner molecule and monitoring estradiol either way.
Point of divergence: Is the fewer-side-effects edge enough to prefer enclomiphene, given it is compounded and unapproved while clomiphene is at least FDA-approved (for women)?
2023 · TRT safety
Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE)
Lincoff AM, et al. · N Engl J Med, 2023
Link to study: Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE)
The largest randomized trial of TRT safety: in ~5,200 high-cardiovascular-risk men, testosterone was non-inferior to placebo for major cardiac events.
Conventional / MD reading
- The largest RCT (~5,200 high-risk men): TRT was non-inferior to placebo for major adverse cardiac events.
- Eases decades of cardiovascular fear; flags atrial fibrillation and requires hematocrit monitoring; showed no diabetes benefit.
Functional & integrative reading
- The cohort was older, obese, high-risk men whose low T largely reflects metabolic disease the trial did not treat.
- Reads "no extra harm" as a floor, not an endorsement of lifelong hormone replacement; address reversible drivers and fertility first.
Point of divergence: Is cardiovascular safety the green light to treat, or beside the point if the underlying metabolic cause goes unaddressed?
2022 · Reference ranges
Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20–44 Years Old
Zhu A, et al. · J Urol, 2022
Link to study: Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20–44 Years Old
Young men have higher normal testosterone than older men, so the one-size 300 ng/dL cutoff under-diagnoses them. Age-specific low-T cutoffs run ~409 (early 20s) down to 350 (early 40s).
Conventional / MD reading
- Using a single 300 ng/dL cutoff for all ages under-calls deficiency in younger men, whose normal range is higher.
- Supports age-specific cutoffs (~409 ng/dL at 20–24) when evaluating men 20–44.
Functional & integrative reading
- Hard proof that a "normal" result can still be low for your age and stage. Treat the man, not the lab's generic cutoff.
- Pairs with finding why a young man's level is low (sleep, body fat, stress) rather than reflexively medicating.
Point of divergence: Both agree the cutoff is too low for young men; they differ on whether to treat against a higher number or to hunt the cause.
2022 · Sleep
Sleep, testosterone and cortisol balance, and ageing men
Liu PY, Reddy RT · Rev Endocr Metab Disord, 2022
Link to study: Sleep, testosterone and cortisol balance, and ageing men
Sleep loss and obstructive sleep apnea lower testosterone and raise afternoon cortisol, tilting the anabolic–catabolic balance toward metabolic harm.
Conventional / MD reading
- Sleep loss and sleep apnea are real, measurable suppressors of testosterone. Screen for them before labeling a man hypogonadal.
- High-dose testosterone can worsen apnea, so sleep must be assessed either way.
Functional & integrative reading
- A centerpiece for the reversible-cause case: fix sleep and apnea and testosterone often recovers.
- Treats sleep as a lever on the underlying metabolic harm, not just the number.
Point of divergence: Is sleep a confounder to correct before diagnosis, or the primary intervention that can make hormone therapy unnecessary?
2021 · Enclomiphene
Efficacy of non-testosterone-based treatment in hypogonadal men: a review
Raheem OA, et al. · Sex Med Rev, 2021
Link to study: Efficacy of non-testosterone-based treatment in hypogonadal men: a review
A review of 25 studies (8 on SERMs) found SERMs raised mean total testosterone from roughly 168 to 366 ng/dL, alongside aromatase inhibitors and hCG, as alternatives to testosterone replacement.
Conventional / MD reading
- Maps the non-testosterone options (SERMs, aromatase inhibitors, hCG) and finds each raises testosterone; SERMs moved mean total T from ~168 to ~366 ng/dL.
- Evidence is mostly small studies; frames these as alternatives for specific cases, not replacements for guideline care.
Functional & integrative reading
- A useful map of the fertility-preserving toolkit functional clinicians reach for before exogenous hormone.
- Reinforces choosing the lever that keeps the body’s own production switched on.
Point of divergence: Are these genuine alternatives for most men, or second-line options for the specific man set on preserving fertility?
2019 · Enclomiphene
Long-term safety and efficacy of clomiphene citrate for hypogonadism
Krzastek SC, et al. · J Urol, 2019
Link to study: Long-term safety and efficacy of clomiphene citrate for hypogonadism
In 400 men, clomiphene (enclomiphene’s parent drug) kept testosterone in range over years: 88% of long-term users reached eugonadism, 77% reported symptom improvement, and 8% reported side effects.
Conventional / MD reading
- One of the longest follow-ups: among men treated over three years, 88% reached normal testosterone and 77% felt better, with side effects in 8%.
- Observational, single drug (clomiphene), so it informs rather than proves the enclomiphene case.
Functional & integrative reading
- Used as evidence that the axis can be coaxed for years rather than replaced for life.
- Still pairs the medication with fixing the reversible drivers underneath.
Point of divergence: Does years of maintained testosterone make a SERM a durable solution, or just a longer-running prop under an unaddressed cause?
2018 · Diagnosis
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Bhasin S, et al. · J Clin Endocrinol Metab, 2018
Link to study: Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
The conventional standard: diagnose only with symptoms plus repeated low morning total T, confirm free T when SHBG is off, find the cause, then treat to mid-normal with monitoring.
Conventional / MD reading
- Sets the diagnostic backbone: symptoms + two morning total T, free T by dialysis/formula when borderline, then find the cause.
- Cautious treatment with explicit contraindications (fertility plans, prostate flags, high hematocrit, recent cardiac events).
Functional & integrative reading
- Endorses the rigor and especially the "ascertain the cause" step, which aligns with root-cause thinking.
- Would push that clause further toward correcting lifestyle and metabolic drivers before exogenous hormone.
Point of divergence: Both demand a confirmed diagnosis; they differ on how hard to exhaust reversible causes before replacing the hormone.
2017 · Reference ranges
Harmonized Reference Ranges for Circulating Testosterone Levels in Men
Travison TG, et al. · J Clin Endocrinol Metab, 2017
Link to study: Harmonized Reference Ranges for Circulating Testosterone Levels in Men
Pooled four large cohorts to set a harmonized normal range (264–916 ng/dL in healthy non-obese men 19–39) and showed much of the variation between labs is just assay differences.
Conventional / MD reading
- Provides a standardized reference range and a way to cross-calibrate assays, improving diagnostic consistency.
- Explains why the same man can get different "normal/low" verdicts from different labs.
Functional & integrative reading
- Underlines that a single number means little without the right assay and context. It reinforces skepticism of one-off readings.
- Supports reading labs against symptoms and trend, not a hard line.
Point of divergence: Both want better numbers; one uses them to firm up the cutoff, the other to argue no single cutoff should decide care.
2017 · Treatment
A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management
Grossmann M, Matsumoto AM · J Clin Endocrinol Metab, 2017
Link to study: A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management
A conservative counterpoint: in functional hypogonadism, address lifestyle and comorbidities first and reserve hormone therapy for clearly low testosterone, while cautioning against off-label SERMs given limited evidence.
Conventional / MD reading
- Argues functional hypogonadism is often driven by obesity and illness, so lifestyle and comorbidity management come before testosterone.
- Cautions explicitly against off-label SERM and aromatase-inhibitor use given thin evidence at the time.
Functional & integrative reading
- Shares the root-cause instinct: treat the drivers, not just the number.
- Parts ways on SERMs, which functional clinicians adopt more readily than this perspective endorses.
Point of divergence: Both want causes addressed first; they split on whether off-label SERMs are a reasonable tool or a step ahead of the evidence.
2016 · Enclomiphene
Enclomiphene for secondary male hypogonadism: efficacy and the FDA-approval question
Rodriguez KM, Pastuszak AW, Lipshultz LI · Expert Opin Pharmacother, 2016
Link to study: Enclomiphene for secondary male hypogonadism: efficacy and the FDA-approval question
A review summarizing enclomiphene’s testosterone benefit and explaining why it remains unapproved: regulators did not accept a testosterone rise on its own as proof of clinical benefit.
Conventional / MD reading
- Synthesizes the trial data and the regulatory story: effective at raising testosterone, but not FDA-approved because a number alone was not accepted as clinical benefit.
- Frames enclomiphene as off-label/compounded in the US, with clomiphene approved only for women.
Functional & integrative reading
- Welcomes a fertility-preserving option but keeps the honest caveat that approval and long-term data are missing.
- Reads "unapproved" as "not yet proven on outcomes," not "unsafe."
Point of divergence: Should an unapproved-but-mechanistically-sound option be offered now, or held until outcome trials clear the FDA bar?
2014 · Enclomiphene
Enclomiphene conserves sperm counts where topical testosterone suppresses them (Phase II RCTs)
Wiehle RD, et al. · Fertil Steril, 2014
Link to study: Enclomiphene conserves sperm counts where topical testosterone suppresses them (Phase II RCTs)
In two randomized trials, enclomiphene raised testosterone and LH like testosterone gel but, unlike the gel, did not suppress sperm production.
Conventional / MD reading
- Randomized evidence that enclomiphene raises testosterone while preserving sperm, the opposite of what exogenous testosterone does to fertility.
- Phase II and short; fertility endpoints are sperm counts, not pregnancies.
Functional & integrative reading
- The fertility-preservation result is the whole appeal: treat low testosterone without shutting the testes down.
- Confirms the mechanism, raising LH/FSH rather than overriding them.
Point of divergence: Both agree fertility is preserved; they differ on whether that alone should move enclomiphene ahead of testosterone for younger men.
2013 · Enclomiphene
Enclomiphene versus testosterone gel: a Phase II dose-finding study
Wiehle R, et al. · BJU Int, 2013
Link to study: Enclomiphene versus testosterone gel: a Phase II dose-finding study
In a dose-ranging Phase II trial, enclomiphene at 25 mg/day reached mean total testosterone of 604 ng/dL, comparable to testosterone gel, while keeping LH elevated.
Conventional / MD reading
- Established a working dose: 25 mg/day brought mean testosterone to ~604 ng/dL, on par with gel, with LH preserved.
- Small, single-blind, short; sets the dose more than it settles outcomes.
Functional & integrative reading
- Shows a normal-range result is achievable without exogenous hormone, keeping the body’s signaling on.
- Anchors the practical 12.5–25 mg dosing later used off-label.
Point of divergence: Is reaching the same testosterone as a gel the win, or is the preserved LH signal the more important difference?
2013 · Enclomiphene
Enclomiphene stimulates testosterone while preventing oligospermia (proof-of-concept)
Kaminetsky J, et al. · J Sex Med, 2013
Link to study: Enclomiphene stimulates testosterone while preventing oligospermia (proof-of-concept)
A head-to-head pilot: enclomiphene and testosterone gel raised total testosterone similarly, but only enclomiphene also raised LH and FSH and preserved sperm production.
Conventional / MD reading
- Early head-to-head signal: enclomiphene matched a gel on testosterone but, unlike the gel, kept LH, FSH and sperm production up.
- Tiny pilot; hypothesis-generating, not practice-changing on its own.
Functional & integrative reading
- The origin of the root-cause pitch: restart the axis rather than replace the hormone from outside.
- Reads intact signaling and fertility as the point, not a bonus.
Point of divergence: Is matching a gel on testosterone enough, or does preserving the body’s own signaling make a SERM the better first move?
2009 · Prostate
Shifting the paradigm of testosterone and prostate cancer: the saturation model
Morgentaler A, Traish AM · Eur Urol, 2009
Link to study: Shifting the paradigm of testosterone and prostate cancer: the saturation model
Proposed that androgen receptors "saturate" at low testosterone (~250 ng/dL), so raising T above that does not proportionally feed prostate growth.
Conventional / MD reading
- Androgen receptors saturate at low T, so more testosterone above ~250 ng/dL does not proportionally feed the prostate.
- Dismantled the reflex fear that TRT causes prostate cancer; PSA monitoring continues.
Functional & integrative reading
- Welcomes the de-risking but stresses prostate health is multifactorial (insulin, inflammation, body fat, diet).
- "Not harmful" is not "protective." Still pursue metabolic and lifestyle optimization.
Point of divergence: Does removing the prostate fear justify broader treatment, or just remove one objection while the root drivers remain?
2002 · Aging
Age trends in serum testosterone in middle-aged men (Massachusetts Male Aging Study)
Feldman HA, et al. · J Clin Endocrinol Metab, 2002
Link to study: Age trends in serum testosterone in middle-aged men (Massachusetts Male Aging Study)
Testosterone fell ~1–2%/yr in middle-aged men, faster within individuals over time. But men in apparent good health had 10–15% higher androgens.
Conventional / MD reading
- Quantifies the age-related decline and shows incident poor health accelerates it.
- Reinforces evaluating symptomatic men alongside their comorbidities.
Functional & integrative reading
- The headline is the 10–15% "good-health bonus": lifestyle and disease burden meaningfully move testosterone.
- Strong support for fixing reversible drivers (obesity, drinking, chronic illness) before or alongside therapy.
Point of divergence: How much of the decline is treatable through health behaviors versus an intrinsic process warranting replacement?
2001 · Aging
Longitudinal effects of aging on serum testosterone (Baltimore Longitudinal Study of Aging)
Harman SM, et al. · J Clin Endocrinol Metab, 2001
Link to study: Longitudinal effects of aging on serum testosterone (Baltimore Longitudinal Study of Aging)
Testosterone and free T fall steadily with age independent of illness, so hypogonadal levels become common: ~20% of men over 60, ~50% over 80.
Conventional / MD reading
- Confirms an age-independent biological decline in T and free T, not just an artifact of illness.
- Justifies considering evaluation or replacement in older men with the lowest levels.
Functional & integrative reading
- Much of the "decline" overlaps with rising body fat and chronic disease, which are modifiable.
- Reads common low levels in older men as partly a lifestyle/metabolic signal, not an inevitability to medicate.
Point of divergence: Is age-related decline a deficiency to replace, or a largely modifiable consequence of how men age?
1999 · Diagnosis
A critical evaluation of simple methods for the estimation of free testosterone
Vermeulen A, et al. · J Clin Endocrinol Metab, 1999
Link to study: A critical evaluation of simple methods for the estimation of free testosterone
The equation now used everywhere to estimate free testosterone from total T, SHBG and albumin. The basis of our calculator.
Conventional / MD reading
- A reliable, low-cost equation to estimate free testosterone from total T, SHBG and albumin.
- Catches men with normal total but low free T because of high SHBG; embedded in guidelines and lab reports.
Functional & integrative reading
- Uses the same normal-total / low-free finding as a prompt to ask why SHBG is high (aging, very low calorie intake, thyroid, liver, insulin).
- The number points to correctable causes upstream, not only a prescription.
Point of divergence: Is a low calculated free T the thing to treat, or a clue pointing upstream to the SHBG drivers?